

**SUPPLEMENTARY PROSPECTUS DATED 11 SEPTEMBER 2023 TO THE PROSPECTUS DATED
16 JUNE 2023**



Aviva plc

Incorporated in England with limited liability (Registered number 02468686)

£7,000,000,000

Euro Note Programme

This Supplementary Prospectus (the “**Supplementary Prospectus**”, which definition shall also include all information incorporated by reference herein) to the base prospectus dated 16 June 2023 (the “**Prospectus**”, which definition includes the Prospectus as supplemented, amended or updated from time to time and includes all information incorporated by reference therein), constitutes a supplementary prospectus for the purposes of Article 23 of Regulation (EU) 2017/1129 as it forms part of the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018, as amended (the “**UK Prospectus Regulation**”) and is prepared in accordance with the £7,000,000,000 Euro Note Programme (the “**Programme**”) established by Aviva plc (the “**Issuer**”).

Terms defined in the Prospectus have the same meaning when used in this Supplementary Prospectus.

This Supplementary Prospectus is supplemental to, and should be read in conjunction with, the Prospectus issued by the Issuer and all documents which are incorporated herein or therein by reference.

This Supplementary Prospectus has been approved by the United Kingdom Financial Conduct Authority (the “**FCA**”), which is the competent authority for the purposes of the UK Prospectus Regulation, as a supplementary prospectus to the Prospectus. The Prospectus constitutes a base prospectus in compliance with the UK Prospectus Regulation for the purpose of giving information with regard to the issue of Notes under the Programme.

The Issuer accepts responsibility for the information contained in this Supplementary Prospectus. To the best of the knowledge of the Issuer (having taken all reasonable care to ensure that such is the

case), the information contained in this Supplementary Prospectus is in accordance with the facts and makes no omission likely to affect its import.

The purpose of this Supplementary Prospectus is to:

1. incorporate by reference the Half Year Report 2023 (as defined below) save for the “News Release” section as outlined in paragraph 1 of this Supplementary Prospectus;
2. incorporate by reference the 2022 Comparative Results (as defined below);
3. update the no significant change statement of the Issuer in the Prospectus; and
4. update the sub-section of the Prospectus entitled “Directors of the Issuer” under “Management of the Issuer” in the section entitled “Description of the Group”.

Any non-incorporated parts of a document referred to herein are either deemed not relevant for an investor or are otherwise covered elsewhere in the Prospectus to which this Supplementary Prospectus relates.

1. DOCUMENTS INCORPORATED BY REFERENCE

Half Year Report 2023

On 16 August 2023, the Issuer published its unaudited interim half year report for the six months to 30 June 2023 (the “**Half Year Report 2023**”). By virtue of this Supplementary Prospectus, the Half Year Report 2023 is hereby incorporated in and forms part of this Supplementary Prospectus (and is thereby incorporated in and forms part of the Prospectus) except that the first twelve pages of the Half Year Report 2023 titled “News Release” shall not be deemed to be incorporated in, and shall not be deemed to form part of, the Supplementary Prospectus or the Prospectus.

2022 Comparative Results under IFRS 17 and IFRS 9

On 19 July 2023, the Issuer published unaudited initial comparative results for the six months to 30 June 2022 and the year to 31 December 2022, restated for the adoption of International Financial Reporting Standard (“**IFRS**”) 17 Insurance Contracts (“**IFRS 17**”) and IFRS 9 Financial Instruments (“**IFRS 9**”) (the “**2022 Comparative Results**”). By virtue of this Supplementary Prospectus, the 2022 Comparative Results are hereby incorporated in and form part of this Supplementary Prospectus (and are thereby incorporated in and form part of the Prospectus).

Alternative Performance Measures

Certain alternative performance measures (“**APMs**”) are included or referred to in the Half Year Report 2023 and the 2022 Comparative Results. APMs are non-GAAP measures, used by the Group within its financial publications to supplement disclosures prepared in accordance with other regulations such as IFRS and Solvency II. The Issuer considers that these measures provide useful information to enhance the understanding of financial performance. The APMs should be viewed as complementary to, rather than a substitute for, the figures determined according to other regulatory measures. An explanation of each such metric's components and calculation method can be found at (i) pages 115 to 128 (incorporated by reference herein) of the Half Year Report 2023 for the half year ended 30 June 2023, and (ii) pages 5 and 11 (incorporated by reference herein) of the 2022 Comparative Results.

2. NO SIGNIFICANT CHANGE

The no significant change statement of the Issuer at page 236 of the Prospectus is updated as set out below:

“There has been no significant change in the financial performance or financial position of the Group since 30 June 2023, being the date to which the Issuer’s last published interim financial information (as set out in the Half Year Report 2023) was prepared.”

3. DIRECTORS

The sub-section of the Prospectus headed “Directors of the Issuer” under “Management of the Issuer” in “Description of the Group” on page 174 of the Prospectus shall be updated to remove “Thomas Lloyd plc” from the list of Mike Craston’s other significant directorships.

4. GENERAL

Copies of all documents or information incorporated by reference in this Supplementary Prospectus and the Prospectus can be obtained from the Issuer as described in the Prospectus or are otherwise available for viewing free of charge on the website of the Regulatory News Service operated by the London Stock Exchange at www.londonstockexchange.com/exchange/news/market-news/marketnews-homes.html.

To the extent that there is any inconsistency between (a) any statement in this Supplementary Prospectus or any statement incorporated by reference into the Prospectus by this Supplementary Prospectus, and (b) any other statement in or incorporated by reference in the Prospectus prior to the date of this Supplementary Prospectus, the statements in (a) above will prevail.

If documents which are incorporated by reference themselves incorporate any information or other documents therein, either expressly or implicitly, such information or other documents will not form part of this Supplementary Prospectus for the purposes of the UK Prospectus Regulation except where such information or other documents are specifically incorporated by reference to this Supplementary Prospectus or where this Supplementary Prospectus is specifically defined as including such information.

Save as disclosed in this Supplementary Prospectus and any supplement previously issued by the Issuer, there has been no other significant new factor, material mistake or inaccuracy relating to information included in the Prospectus since publication of the Prospectus.

No person is authorised to give any information or to make any representation not contained in the Prospectus or this Supplementary Prospectus, and any information or representation not so contained must not be relied upon as having been authorised by or on behalf of the Issuer or the Dealers. The delivery of the Prospectus and/or this Supplementary Prospectus at any time does not imply that there has been no change in the affairs of the Issuer since the date hereof, or that the information contained in either of them is correct as at any time subsequent to each of their respective dates.

THIS SUPPLEMENTARY PROSPECTUS IS DATED 11 SEPTEMBER 2023